UCB Joins the Chase for Immune System Reset With $2B Acquisition
Candid Therapeutics brings to UCB two clinical-stage T cell engagers in development for autoimmune disorders. To accept UCB’s offer, Candid terminated its reverse merger with Rallybio.
Candid Therapeutics Strikes Up Merger With Rallybio to Advance Its Autoimmune Drug Pipeline
Along with the reverse merger, Candid Therapeutics announced $505 million in private financing to support its pipeline of T cell engagers for autoimmune disease. Lead program cizutamig is on track to begin global Phase 2 testing in myasthenia gravis and interstitial lung disease.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
BMS Tries Again With T Cell Engagers, Turning to Janux to Develop New Tumor-Activated Therapy
Bristol Myers Squibb is paying $50 million to begin a collaboration with Janux Therapeutics, a company that develops T cell engagers that activate specifically at the site of the tumor. It’s the second big pharma alliance for Janux, which has been working with Merck.